A new ADHD drug targets three brain chemicals instead of two. Here’s what that means

Authors: Jack Janetzki, Lisa Ellett
Publication:
Published: Unknown date
Source: Crossref
Back to Search View Original Cite This Article

Related Articles

A Multiscale Structural, Pharmacokinetic–Pharmacodynamic and Systems Pharmacology Framework Exploring a Plausible Interaction Between Cenobamate and Low-Dose Clobazam in Drug-Resistant Epilepsy

Gonzalo Miranda - Unknown

Read More
Analytical concordance of targeted next-generation sequencing and whole-genome sequencing for Mycobacterium tuberculosis drug resistance and lineage determination in West Java, Indonesia

Gusti Ayu Prani Pradani, Almira Alifia et al. - Unknown

Read More
Overcoming ADHD stigma in the classroom: a pilot study on the effectiveness of an ADHD awareness training

Saskia van der Oord, Finja Marten et al. - Unknown

Read More
Who Marks the Trial Record When a Drug Is Withdrawn? Regulatory-Status Metadata on Pivotal Publications for US Safety Withdrawals, 1990 to 2024

Phani Kurada - Unknown

Read More
megaMine: a scalable, rule-based framework for mining gene-cancer-drug evidence from biomedical literature

Muhammad JUNAID, Karolina Hanna Prazanowska et al. - Unknown

Read More
Journal Ideas PyMinds Charcha More
PORE

About

About Us

Resources

Help Centre Research Guides CiteScore

Legal

Terms of Service Privacy Policy Cookie Policy Accessibility

Connect

Contact Us
© 2026 PORE. Content available under CC BY-NC 4.0